We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
+29.88%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
+$38.4M
(+29%)
Cap. Flow
+$19.7M
Cap. Flow
% of AUM
11.56%
Top 10 Holdings %
Top 10 Hldgs %
54.57%
Holding
80
New
11
Increased
19
Reduced
14
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$6.27M |
| 2 |
Intellia Therapeutics
NTLA
|
+$3.52M |
| 3 |
Compass Therapeutics
CMPX
|
+$3.32M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$2.28M |
| 5 |
Solid Biosciences
SLDB
|
+$2.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axogen
AXGN
|
+$2.12M |
| 2 |
Inhibrx
INBX
|
+$1.91M |
| 3 |
uniQure
QURE
|
+$1.85M |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
+$1.16M |
| 5 |
Prothena Corp
PRTA
|
+$1.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.96% |
| 2 | Technology | 19.61% |
| 3 | Energy | 3.55% |
| 4 | Materials | 0.54% |
| 5 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Phreesia
PHR
$660M
| $1.87M | 1.1% |
110,700
-4,000
| -3% | -$82.5K |
|
27
EQT Corp
EQT
$30.7B
| $1.86M | 1.09% |
34,619
| – | – |
|
28
Harrow
HROW
$1.66B
| $1.67M | 0.98% |
34,000
-6,000
| -15% | -$252K |
|
29
Travere Therapeutics
TVTX
$5.16B
| $1.64M | 0.96% |
43,000
-60
| -0.1% | -$1.95K |
|
30
Foghorn Therapeutics
FHTX
$305M
| $1.52M | 0.89% |
281,730
| – | – |
|
31
United Therapeutics
UTHR
$22.5B
| $1.46M | 0.86% |
3,000
| – | – |
|
32
Ultragenyx Pharmaceutical
RARE
$2.81B
| $1.43M | 0.83% |
62,000
+40,000
| +182% | +$1.32M |
|
33
Alkermes
ALKS
$8.62B
| $1.4M | 0.82% |
50,000
| – | – |
|
34
Nektar Therapeutics
NKTR
$2.19B
| $1.31M | 0.77% |
31,000
+26,979
| +671% | +$1.51M |
|
35
Apogee Therapeutics
APGE
$10.1B
| $1.21M | 0.71% |
16,000
| – | – |
|
36
Verastem
VSTM
$505M
| $1.16M | 0.68% |
+150,000
| New | +$1.34M |
|
37
Axsome Therapeutics
AXSM
$11.4B
| $1.11M | 0.65% |
6,061
+61
| +1% | +$8.52K |
|
|
MASI
38
DELISTED
Masimo
MASI
| $1.08M | 0.63% |
8,280
| – | – |
|
39
10x Genomics
TXG
$5.49B
| $962K | 0.56% |
+59,000
| New | +$891K |
|
40
Xenon Pharmaceuticals
XENE
$6.38B
| $941K | 0.55% |
21,000
| – | – |
|
41
Pacific Biosciences
PACB
$422M
| $935K | 0.55% |
500,000
| – | – |
|
|
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
| $921K | 0.54% |
57,000
-10,000
| -15% | -$132K |
|
43
Freeport-McMoran
FCX
$84.5B
| $917K | 0.54% |
18,046
+2
| +0% | +$87 |
|
|
VTYX
44
DELISTED
Ventyx Biosciences
VTYX
| $910K | 0.53% |
100,827
+2,000
| +2% | +$14.9K |
|
45
Pharvaris
PHVS
$2.34B
| $828K | 0.48% |
29,847
+15,000
| +101% | +$361K |
|
46
Illumina
ILMN
$27.9B
| $787K | 0.46% |
+6,000
| New | +$704K |
|
|
47
uniQure
QURE
$2.73B
| $737K | 0.43% |
30,789
-47,939
| -61% | -$1.85M |
|
48
Halozyme
HALO
$9.14B
| $680K | 0.4% |
10,100
| – | – |
|
|
BHVN
49
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $670K | 0.39% |
+59,365
| New | +$670K |
|
50
BridgeBio Pharma
BBIO
$15.8B
| $665K | 0.39% |
8,688
| – | – |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q4 2025 Portfolio in Review
As of Q4 2025, Birchview Capital held 80 positions worth $171M, up 29% from $132M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Birchview Capital deployed $19.7M of net new capital in Q4 2025, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Lam Research: 40,329 shares worth $6.9M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Inhibrx, an estimated $1.91M trimmed.
- Birchview Capital's largest Q4 2025 buy was Lam Research: 40,329 shares worth $6.9M.
- Birchview Capital added most to Intellia Therapeutics in Q4 2025, an estimated $3.52M increase.
- Birchview Capital's biggest Q4 2025 reduction was Inhibrx, cutting an estimated $1.91M.
- Birchview Capital fully exited Axogen in Q4 2025, selling an estimated $2.12M.
- Birchview Capital's ten largest holdings make up 55% of its $171M portfolio in Q4 2025.
- Birchview Capital opened 11 new positions and closed 12 in Q4 2025.
- Birchview Capital's portfolio value rose 29% quarter-over-quarter to $171M.
Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.